I+Ve got a question: how long should we treat relapsed CLL?
M
Moritz Fürstenau
(1Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany)
Article Details
Journal
Blood
Volume / Issue
Vol. 145, Issue 22
Published
May 29, 2025
Pages
2536-2538
ISSN
0006-4971
Publisher
Elsevier BV
Authors (1)
M
Moritz Fürstenau
1Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany
Related Articles from this Journal
NOTCHing the MSC-endothelial interplay in the HSC niche
Simón Méndez-Ferrer
Aug 2026
10.1182/blood.2026034119
Procr+ endothelial progenitor cells govern hematopoiesis through fine-tuning mesenchymal stem cell niche signals
Chang Xu, Xue Lv et al.
Aug 2026
10.1182/blood.2025031474
Li C, Wu B, Li Y, et al. Loss of sphingosine kinase 2 promotes the expansion of hematopoietic stem cells by improving their metabolic fitness. <i>Blood</i> . 2022;140(15):1686-1701.
Aug 2026
10.1182/blood.2026035281
Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis
Karthik Chetlapalli, Satoko Ito et al.
Aug 2026
10.1182/blood.2025032290
Granulopoiesis under attack by mutant IDH1
Hideyo Hirai
Aug 2026
10.1182/blood.2026034486